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Background: Alpha-lipoic acid (ALA), a naturally occurring compound, exerts powerful protective effects in various
cardiovascular disease models. However, its role in protecting against diabetic cardiomyopathy (DCM) has not been
elucidated. In this study, we have investigated the effects of ALA on cardiac dysfunction, mitochondrial oxidative
stress (MOS), extracellular matrix (ECM) remodeling and interrelated signaling pathways in a diabetic rat model.
Methods: Diabetes was induced in rats by I.V. injection of streptozotocin (STZ) at 45 mg/kg. The animals were
randomly divided into 4 groups: normal groups with or without ALA treatment, and diabetes groups with or
without ALA treatment. All studies were carried out 11 weeks after induction of diabetes. Cardiac catheterization
was performed to evaluate cardiac function. Mitochondrial oxidative biochemical parameters were measured by
spectophotometeric assays. Extracellular matrix content (total collagen, type I and III collagen) was assessed by
staining with Sirius Red. Gelatinolytic activity of Pro- and active matrix metalloproteinase-2 (MMP-2) levels were
analyzed by a zymogram. Cardiac fibroblasts differentiation to myofibroblasts was evaluated by Western blot
measuring smooth muscle actin (α-SMA) and transforming growth factor–β (TGF-β). Key components of underlying
signaling pathways including the phosphorylation of c-Jun N-terminal kinase (JNK), p38 MAPK and ERK were also
assayed by Western blot.
Results: DCM was successfully induced by the injection of STZ as evidenced by abnormal heart mass and cardiac
function, as well as the imbalance of ECM homeostasis. After administration of ALA, left ventricular dysfunction
greatly improved; interstitial fibrosis also notably ameliorated indicated by decreased collagen deposition, ECM
synthesis as well as enhanced ECM degradation. To further assess the underlying mechanism of improved DCM by
ALA, redox status and cardiac remodeling associated signaling pathway components were evaluated. It was shown
that redox homeostasis was disturbed and MAPK signaling pathway components activated in STZ-induced DCM
animals. While ALA treatment favorably shifted redox homeostasis and suppressed JNK and p38 MAPK activation.
Conclusions: These results, coupled with the excellent safety and tolerability profile of ALA in humans,
demonstrate that ALA may have therapeutic potential in the treatment of DCM by attenuating MOS, ECM
remodeling and JNK, p38 MAPK activation.
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Diabetes is one of the major health problems around the
world. It is estimated that the number of diabetic
patients will increase from 135 million in 1995 to 300
million by the year 2025 [1]. Diabetic patients have a 2-
to 5-fold increased risk of developing heart failure, one
of the most greatest contributors to morbidity and mor-
tality [2]. Diabetic cardiomyopathy (DCM) is defined as
the ventricular dysfunction that occurs in diabetic
patients independent of another cause, such as coronary
artery disease or hypertension [3,4]. The term “DCM”
was initially introduced by Rubler in 1972 based upon
post-mortem finding in diabetic adults who had HF in
the absence of other co-morbid conditions [5]. The term
now also embraces diabetic individuals with diastolic
dysfunction. Somaratne recently reported that 56% of
diabetic patients had DCM [6]. Although the etiology of
DCM is poorly understood, the pathophysiology of
DCM is believed to be multifactorial. Existing evidences
suggests that persistent hyperglycemia-induced MOS is
a significant contributor to DCM [7,8]. Indeed, the activ-
ity of several anti-oxidant enzymes is decreased in the
diabetic heart in both rats and humans [9].
Cardiac fibrosis is a major feature of DCM [10]. In this
condition, an over-production of extra cellular matrix
(ECM) protein leads to increased myocardial stiffness
and consequent cardiac dysfunction, ultimately resulting
in cardiac failure. Therefore, assessment of the balance
between ECM synthesis and degradation is a good way
to predict the development of diabetes-induced cardiac
fibrosis. Elucidating the underlying mechanism and sig-
naling pathways involved in ECM remodeling is also,
therefore, of great importance.
The harmful effects of oxidative stress on the diabetic
heart are well established. These include abnormal gene
expression, altered signal transduction, and activation a
number of secondary messenger pathways which lead to
cell death and cardiac fibrosis [11-13]. Given the central
role of oxidative stress in the pathogenesis of diabetes
and diabetic cardiomyopathy, there is growing interest
in the use of antioxidants as a complementary thera-
peutic approach. Numerous studies demonstrated that
ameliorating oxidative stress through antioxidant treat-
ment might be an effective strategy for reducing DCM
[14,15]. However, traditional antioxidant vitamin E and
C clinical trials have failed to demonstrate relevant clin-
ical benefits on cardiovascular disease [7]. Thus there is
an urgent need for clinically effective antioxidants. ALA
(also known as 1, 2-dithiolane-3-pentanoic acid and
thioctic acid) is a naturally occurring compound
involved in mitochondrial dehydrogenase reactions and
has recently gained a considerable amount of attention
as a novel antioxidant. While the beneficial role of ALA
in improving diabetic neuropathy has been extensivelystudied and clinically approved, the effect of ALA on the
development and progression of DCM has not yet to be
determined. Research studies have demonstrated that
intraperitoneal administration of ALA to STZ diabetic
Wistar rats normalizes thiobarbituric acid reactive sub-
stances (TBARS) level in plasma, retina, liver, and pan-
creas [16]. Furthermore, in cardiovascular disease,
dietary supplementation with ALA has been successfully
employed in a variety of in vivo models: ischemia–reper-
fusion, heart failure, and hypertension [17].
Our previous study [18] and Bojunga [19] both
showed that ALA can prevent inappropriate apoptosis in
the hearts of diabetic rats. Therefore, in the present
study, we extended this work by examining the molecu-
lar mechanisms underlying the protective effects of ALA
against DCM. This was done by evaluating MOS, car-
diac ECM synthesis and degradation and related signal-
ing pathway activities in ALA-treated STZ-induced
diabetic rats. To our knowledge, this is the first in vivo
study that investigates the effect of ALA treatment on
cardiac ECM remodeling in a diabetic rat model. The
results show the potential of ALA in the treatment of
DCM.Materials and methods
Animals and procedures
The experimental and feeding protocols were approved
and in accordance with the laws and regulations control-
ling experiments on live animals in China and the Asian
Convention for the Protection of Vertebrate Animals
used in Experimental and Other Scientific Purposes.
Eight week old male Wistar rats, weighing 200 to 250 g,
were purchased from the Department of Experimental
Animals in Peking (China). They were maintained on
12 h light/dark cycle at 21°C and fed with a standard
chow and were given access to tap water ad libitum.
Rats were rendered diabetes by a single tail intravenous
injection of STZ (45 mg/kg, Sigma) dissolved in 0.1 M
sodium citrate buffer, pH 4.5 at 4°C. The STZ induced
rat model is a well established model for the study dia-
betic cardiomyopathy [20]. Insulin supplementation in
STZ-induced diabetic animals leads to an improvement
of left ventricle (LV) function, indicating the role of
hyperglycemia in cardiac dysfunction in this model [21].
Only rats with blood glucose levels ≥16.7 mmol/l 5 days
after STZ injection were used in this study. Age-
matched non-diabetic Wistar rats were injected with so-
dium citrate buffer and used as controls. After 1 week
following injection STZ, rats were treated with either
ALA (100 mg/kg per day i.p.) or vehicle for 11 weeks.
The animals were randomly divided into 4 groups, each
with 8 rats: normal control (NC), ALA treated control
(NC+ALA), non-treated diabetes (STZ) and ALA
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12 weeks after STZ injection.
Cardiac function evaluation
At the end of the experiment, rats were anesthetized
with chloral hydrate (100 mg/kg, i.p.), and cardiac func-
tion was determined by invasive hemodynamic evalu-
ation methods. A pressure tip-catheter was positioned
into the left ventricle (LV) to record LV pressure-data
changes representative of cardiac systolic and diastolic
performance. LV diastolic function was quantified by the
left ventricular end-diastolic pressure (LVEDP) and max-
imum rate of fall of left ventricle pressure (-dP/dtmax).
LV systolic function was quantified by the left ventricular
end-systolic pressure (LVSP) and maximum rate of rise
of left ventricle pressure (+dP/dtmax). (BL-420E + sys-
tem, Tai-meng Instrument Inc., Sichuan, China).
Tissue preparation
The heart was excised from the chest, trimmed of atria
and large vessels and weighed. First, a mid left ventricu-
lar (LV) section was cut perpendicularly along the longi-
tudinal axis and fixed in phosphate-buffered 20%
formaldehyde. Histological paraffin-embedded sections
(5 μm) were then prepared for Sirius red staining. Some
hearts tissue was used for the immediate extraction of
mitochondria and some was rapidly frozen in liquid ni-
trogen and stored at -80 °C for subsequent assay.
Sirius red staining for interstitial collagen content
measurements
LV sections were stained with Sirius Red (Polyscience,
Inc, Warrington, PA) to measure interstitial fibrosis.
Interstitial collagen was quantified at a final magnifica-
tion of 200× with a polarized microscope (Olypus,
America) connected to a video camera (Nikon, Japan).
Perivascular fibrosis was not assessed. The content of
interstitial collagen (expressed as the fractional area of
the entire cross-section) was averaged over nine fields
selected across the septal wall and free wall.Measurements of mitochondrial oxidative biochemical
parameters
Briefly, hearts were excised and washed in cold PBS and
then homogenized in cold lysis buffer supplemented
(250 mM/L sucrose, 3 mM/L HEPES and 0.5 mmol/L
EDTA pH 7.4). The homogenate was centrifuged twice
at 750 g at 4°C for 10 min and debris discarded. The
supernatant from the second spin was removed to fresh
tubes and centrifuged twice at 10,000 g at 4°C for
10 min. The final mitochondrial pellet was resuspended
in lysis buffer. The content of malondialdehyde (MDA)
in the myocardium mitochondrion was assayed usingthiobarbituric acid, and the content of reduced/oxidized
glutathione ratio (GSH/GSSG), and the activities of
superoxide dismutase (SOD) in the myocardium mito-
chondria was measured by spectophotometric assays. All
procedures were followed by the manufacturer’s instruc-
tions. (Jiancheng Inc., Nanjing, China).Western blot analysis
The left ventricular tissue of rat hearts were extracted as
above and protein concentration was measured using
the Bio-Rad protein assay (BioRad, Richmond, CA). Ap-
proximately 50 μg protein was loaded onto 8% or 10%
SDS-PAGE and transferred to a nitrocellulose mem-
brane. The membranes were blocked in 5% dried milk in
Tris-buffered saline (TBS) containing 0.1% Tween 20 for
1 h, and subsequently incubated overnight with primary
antibodies diluted in 5% dried milk–TBS containing
0.1% Tween 20. The primary antibodies were: JNK, p38
and ERK (Cell Signaling); TGF β1 and β-Actin (Santa
Cruz biotechnology); TIMP-2 (Calbiochem, Bad Soden,
Germany); α-SMA, type I and II collagen (abcam USA).
Membranes were washed in TBS containing 0.1% Tween
20 and incubated for 1 h with secondary antibodies
(Santa Cruz biotechnology). Bands were visualized using
an enhanced chemiluminescense detection kit (Pierce
Co.). Quantification of bands was done by gel densitom-
etry with gel image analysis system (American UVP Co).Gelatin Zymogram
Heart tissue extracts were loaded onto 8% SDS-PAGE
gels containing 1 mg/ml gelatin under non reducing
conditions and were run at 120 V for 90 min together
with molecular weight standards. Gels were then washed
four times in zymogram renaturing buffer (2.5% Triton
X-100) and incubated overnight in zymogram develop-
ment buffer (50 mM Tris-HCl, PH 7.5, 200 mM NaCl,
5 mM Cacl2, 0.02% NaN3). Gels were then stained with
Coomassie Blue R-250 followed by destaining with 40%
(v/v) Methanol, 10% (v/v) Acetic Acid and 50% water.
Clear bands of MMP activity were visible against the
blue background.Statistical analysis
All statistical operations were performed on a personal
computer with the software program SPSS v11.5. Data
were collected from repeated experiments and are pre-
sented as mean ± SD. One-way ANOVA was used to
compare the difference in the 4 groups and Student
Newman Keuls Test (SNK) was used for between any 2
groups statistical analysis. P< 0.05 was considered statis-
tically significant.
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General features
STZ-induced diabetic animals exhibited increased blood
glucose levels (28.4 ± 2.8 vs 6.4 ± 0.2 mmol/L) along with
decreased body weight (273 ± 45 vs 480 ± 35 g). Diabetic
animals also have increased the heart to body weight
ratio levels compared to normal control rats (3.25 ± 0.25
vs 2.62 ± 0.16 mg/g). The ALA treatment significantly
decreased the heart to body weight ratio, although not
back to the normal level in NC group without altering
the body weight and blood glucose in diabetic animals;
while the ALA treatment in NC animals did not make
any change to body weight, heart weight and glucose
level, indicating the ALA is well tolerated by the animals
and the effects in STZ groups are diabetic specific
(Table 1).
ALA ameliorates diabetes-induced cardiac dysfunction
To assess cardiac function, we positioned a pressure
detecting catheter into the carotid artery and the LV.
After 11 weeks of established diabetes, heart rate (HR)
was significantly decreased in STZ group compared to
the NC group. This is consistent with diabetes asso-
ciated dysfunctional cardiac autonomic neuropathy.
ALA treatment significantly reversed the HR to the con-
trol value. The STZ group also exhibited markedly
impaired diastolic function as indicated by an increase
in LVEDP and a decrease in -dp/dtmax. There was also
impairment of systolic function as shown by a decrease
in LVSP and +dp/dtmax. This impaired cardiac function
was partially restored by ALA treatment (Figure 1).
ALA ameliorates diabetes-induced cardiac fibrosis
The total collagen fraction (as determined by red stain-
ing) (Figure 2A) was higher in the STZ group compared
to NC group, indicating the presence of cardiomyopathy
in the diabetic animals. To specifically identify the types
of collagen content deposited in the interstitial area, we
used polarized light to observe collagen Type I (orange
staining) and Type III (green staining). The deposition
of both types of collagen was increased in STZ group
compared to the NC group (Figure 2B), which is consist-








NC 8 6.44 ± 0.24 480± 35 2.62 ± 0.16
NC+ALA 8 6.26 ± 0.19 492± 35 2.60 ± 0.18
STZ 8 28.41 ± 2.84* 273± 45* 3.25 ± 0.25*
STZ+ALA 8 26.25 ± 3.49* 277± 20* 3.06 ± 0.23*#
Eight rats per group. Data are presented as mean values ± standard deviation.
*p< 0.05 vs. NC group; # p< 0.05 vs. STZ group.treatment of STZ-induced diabetic rats greatly reduced
the deposition of these compounds (Figure 2).
ALA ameliorates diabetes-induced myocardial MOS
As shown in Figure 3, there were considerably increased
MDA levels, a decreased GSH/GSSG ratio and attenu-
ated activity of SOD in myocardial mitochondria of dia-
betic rats compared to control rats. Interestingly, all
these changes were significantly ameliorated by ALA
treatment. This indicates that ALA administration can
improve diabetes-induced MOS damage.
ALA decreases the TGF-β, α-SMA, and TIMP-2 expression
and increases cardiac active- and pro- MMP-2
To evaluate the role of ALA in maintaining extracellular
matrix homeostatsis and the preventing cardiac fibrosis,
TGF-beta, α-SMA and TIMP-2 were determined as mar-
ker of ECM synthesis, while MMP-2 was assayed as an
indicator of ECM degradation. STZ-treated diabetic rats
had significantly increased LV expression of TGF-βand
α-SMA (Figure 4A, 4B), consistent with enhanced ECM
synthesis contributing to the increase in cardiac collagen
concentration (Figure 2). ALA treatment for 11 weeks
significantly decreased LV expression of TGF-β and
α-SMA in the diabetic rats, but had no effect on their
expression in control rats. As indicator of extracellular
matrix degradation, TIMP-2 was shown to be signifi-
cantly increased in STZ-induced diabetic rats (Figure 4C),
consistent with significantly decreased cardiac gelatinoly-
tic activity of active- and pro- MMP-2 levels (Figure 4D)
similarly, there was a marked decrease in gelatinolytic
activity of active MMP-2 levels (Figure 4E, active
MMP-2/Pro-MMP-2). There was no change in the
MMP-9 expression and activity in the heart tissues
of diabetic rats (data not shown). ALA treatment was
able to significantly decrease LV TIMP-2 expression and
MMP-2 gelatinolytic activity, but had no markedly
effects on basal LV TIMP-2 expression or MMP-2 gelati-
nolytic activity over the 11 weeks treatment period.
ALA reduced diabetes-induced MAPK activation
To further assess the signaling pathways potentially
involved in the cardiac remodeling process induced by
diabetes, we examined key components of the MAPK
pathways in the treatment groups. As shown in Figure 5,
there was marked increase the JNK (Figure 5A) and p38
MAPK (Figure 5B) activation in the heart tissues of dia-
betic rats compared to the NC group, ALA treatment of
diabetic rats for 11 weeks significantly mitigated JNK
and p38 MAPK activation. There was no change in the
ERK activation in the heart tissues of diabetic rats com-
pared to the NC group; and ALA treatment of diabetic
rats has no significant effect on ERK activation
(Figure 5C).
Figure 1 Diabetes-induced left ventricular dysfunction were improved by ALA treatment. Cardiac dysfunction were evaluated by
measuring (A) heart rate (HR), (B) left ventricular end-diastolic pressure (LVEDP), (C) maximum rate of fall of left ventricle pressure (-dP/dtmax), (D)
left ventricular end-systolic pressure (LVSP), (E) maximum rate of rise of left ventricle pressure (+dP/dtmax). Eleven weeks of STZ-induced diabetes
was associated with decrease in HR, LVSP and ± dp/dtmax and an increase in LVEDP, which were significantly improved by ALA treatment for
11 weeks. Results are presented as mean values ± standard deviation. *p< 0.05 vs Control group, #p< 0.05 vs. STZ group, n = 8 per group.
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Cardiac failure is a leading cause of the mortality in dia-
betic patients, and is, in part due to DCM. Given the im-
portant contributory role of oxidative stress in DCM,
antioxidant supplementation has been proposed as an
intervention. The present study explored the protective
role of ALA on DCM in the STZ-induced diabetic rat
model.
Our results demonstrated that STZ injection success-
fully induced diabetes and DCM as indicated by a de-
crease in heart rate, increase in cardiac dysfunction and
increased collagen deposition in heart tissues. Interest-
ingly, all of these cardiac abnormalities were improved
by the administration of ALA. As expected, we have also
found the evidence of increased cardiac fibrosis, as sug-
gested by increased TGF-β, α-SMA, TIMP-2 and
reduced MMP-2 activity in the diabetic rats, with all
these being amelioration by ALA treatment. The obser-
vation of attenuated MPAK signaling pathway activation
(JNK, p38 MAPK) after ALA administration confirmed
our hypothesis that reduced MPAK signaling may con-
tribute to the protective effect of ALA. These findings
suggest that ALA treatment may represent a realistic
strategy for limiting the progression of cardiac fibrosis
associated with diabetes.
ROS production is thought to be an important contrib-
uting factor in the development and the progression of
diabetic cardiomyopathy [7-9,22]. Inhibition of ROS by
over-expression of antioxidant enzymes using transgenicmethods in the heart reversed diabetic cardiomyopathy
in animal models of both type 1 and type 2 diabetes
[3,13,23-25]. However, these methods currently are not
practical in clinical practice. In contrast, ALA has been
safely used in the clinical management of symptomatic
diabetic neuropathy in Germany for more than 30 years.
Recently, ALA has been shown to have beneficial effects
on treatments of diabetic complications by decreasing
ROS generation and increasing glutathione and SOD ac-
tivity [26]. These results support our experimental data,
demonstrating that ALA treatment reduces cardiac dys-
function and remodeling via inhibiting MOS.
Evidence from human and experimental models of dia-
betic cardiomyopathy [15] has implicated cardiac fibrosis
as a strong pathological contributor. Cardiac fibrosis
leads to increased LV stiffness and decreased ventricular
wall compliance, resulting in both systolic and in par-
ticular diastolic dysfunction [27]. The ECM remodeling
plays an important role in cardiac fibrosis. The amount
of extra cellular collagen is caused by an imbalance be-
tween synthesis and degradation. Our previous study
[18], and others studies demonstrated that hypergly-
cemia increased MOS [28], stimulates cardiac fibroblasts
expression TGF-β in vivo [29]. TGF-β is involved in the
differentiation of fibroblasts to myofibroblasts [30], and
causes excessive collagen production, accompanied by
an increase in α-SMA, a surrogate maker of fibroblasts
to myofibroblasts. Here we showed that an increase oxi-





NC NC+ALA STZ STZ+ALA
Figure 2 (See legend on next page.)
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Figure 2 Diabetes induced cardiac fibrosis. (A) The red color of Sirius red staining under the common microscope indicates total collagen
deposition, representative images are from NC, NC+ALA, STZ and STZ +ALA (200 ×magnification). (B) Type I and II collagen deposition were
shown by orange and green color under the polarized light respectively, representative images are from NC, NC+ALA, STZ and STZ+ALA. (C)
The protein level of type I and II collagen were determined by western blot, β-Actin was used as loading control. Bar graph, density analysis
results from 8 rats per group. Results are mean values ± standard deviation. *p< 0.05 vs Control group, #p< 0.05 vs. STZ group.
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increase TGF-β and α-SMA expression, but both were
attenuated by ALA treatment. Together, these finding
indicated that oxidative stress in diabetic rat hearts may
contribute to fibroblasts to myofibroblasts differenti-
ation, with increased collagen Type I and Type III ex-
pression resulting in cardiac remodeling.
Matrix metalloproteinases (MMPs) belong to a family
of enzymes with proteolytic activity that plays an import-
ant role in EC matrix degradation. Indeed MMP-2, is
involved in the pathogenesis of a wide viriety of cardio-
vascular disorders [31,32]. Moreover, MMP-2 has re-
cently been shown to be a direct mediator of ventricular
remodeling and systolic dysfunction [33]. Several studies
in vivo demonstrated that cardiac fibrosis in diabetic car-
diomyopathy is associated with a decrease in MMP-2 ex-
pression/activity [34-36]. The activity of MMPs is tightly
controlled by tissue inhibitors of MMPs (TIMPs), and
changes in the MMP/TIMP ratio, therefore, may lead to
changes in EC matrix. Our results, demonstrated that
ALA treatment ameliorated cardiac dysfunction,
decreased LV Type I and III collagen deposition, reduced
TIMP-2 and increased MMP-2 activity in STZ-induced
diabetic cardiomyopathy. It is likely that oxidative stress
in diabetic rat hearts may contribute to cardiacFigure 3 ALA treatment ameliorated diabetes-induced myocardial mi
measuring (A) malondialdehyde (MDA) (B) endogenous antioxidants reduc
GSH and GSSG (E) superoxide dismutase (SOD) activity. Results are mean v
STZ group.remodeling partly through decreasing cardiac gelatinoly-
tic activity of active- and pro- MMP-2 levels (as shown in
Figure 4D), especially as there was a marked increase in
gelatinolytic activity of active MMP-2 levels (as shown
in Figure 4E, active MMP-2/Pro-MMP-2).
With respect to the signaling pathway potentially
involved in these responses, we found that hypergly-
cemia caused activation of JNK and p38 MAPK in heart
tissue. The major members of MAPKs found in cardiac
tissue include ERK1/2, JNK and p38 MAPK and these
are most strongly activated by oxidative stress, hypergly-
cemia and proinflammatory cytokines [37]. Several stud-
ies have shown that hyperglycemia induced JNK and p38
MAPK activations can be suppressed by antioxidants
[38,39]. Furthermore, pharmacological inhibition of p38
MAPK signaling can decrease the collagen content in
DCM [40,41]. Our results are in agreement with these
studies, demonstrating enhanced activation JNK and p38
MAPK in DCM model, and increased TGF-β expression
and decreased pro- and active-MMP2, all resulting in
cardiac remodeling. Additionally our results show that
ALA treatment can significantly ameliorate cardiac re-
modeling by suppressing the activation of JNK and p38
MAPK, decreasing the TGF-β expression and increasing
pro and active –MMP2, all without altering prevailingtochondrial oxidative stress. Myocardial MOS were determined by
ed glutathione (GSH) (C) oxidized glutathione (GSSG) (D) the ratio of
alues ± standard deviation. *p< 0.05 vs Control group, #p< 0.05 vs.
Figure 4 ALA treatment decreased the TGF-β,α-SMA, and TIMP-2 expression and increased cardiac active- and pro- MMP-2 levels. The
protein expression of TGF-β (A), α-SMA (B), and TIMP-2 (C) were determined by Western blot with specific antibodies as indicated, β-Actin was
used as loading control. Cardiac active- and pro- MMP-2 (D/E) levels were assayed by zymogram. Representative image, bar graph, density
analysis results from 8 hearts per group. Data represent mean ± standard deviation. *p< 0.05 vs Control group, #p< 0.05 vs. STZ group.
Figure 5 ALA Reduces diabetes-induced myocardial activation of JNK and P38. Total protein was obtained from the hearts of STZ-induced
diabetic rats and vehicle rats. Phosphorylated and total JNK, P38 and ERK were determined by Western blot with specific antibodies as indicated.
The extent of JNK (A), P38 (B) and ERK (C) phosphorylation was quantified by phosphorylated protein/total protein. Representative image, bar
graph, density analysis results from 8 hearts per group. Data represent mean ± standard deviation. *p< 0.05 vs Control group, #p< 0.05 vs.
STZ group.
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dative stress and stress signaling play an important role
in development of cardiac remodeling in DCM, but
these effects can be reversed.
Conclusion
Collectively, under STZ-induced diabetic conditions,
cardiac fibrosis is associated with increased synthesis
and decreased degradation of ECM. This is accompanied
by increased differentiation of cardiac fibroblasts to
myofibroblasts and reduced MMP-2 activity, concomi-
tant with increased mitochondrial oxidative damage and
elevated expression and activation of JNK, p38 MAPK
and TGF-β. All these changes can be reversed by ALA,
suggesting that ALA possesses therapeutic potential in
the treatment of DCM.
Abbreviations
α-SMA: Smooth muscle actin; ALA: Alpha-Lipoic acid; DCM: Diabetic
cardiomyopathy; +dp/dt: Maximum rate of rise of left ventricle pressure; -dp/
dt: Maximum rate of fall of left ventricle pressure; ECM: Extracellular matrix;
GSH/GSSG: Reduced/oxidized glutathione ratio; HR: Heart rate; JNK: c-Jun N-
terminal kinase; LV: Left ventricular; LVEDP: Left ventricular end-diastolic
pressure; LVSP: Left ventricular end-systolic pressure; MDA: Malondialdehyde;
MMP-2: Matrix metalloproteinase-2; MMPs: Matrix metalloproteinases;
MOS: Mitochondrial oxidative stress; SNK: Student newman keuls test;
SOD: Superoxide dismutase; STZ: Streptozotocin; TBS: Tris-buffered saline;
TGF-β: Transforming growth factor-β; TIMP-2: Tissue inhibitor of
metalloproteinase-1.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
All authors fulfill the criteria for authorship. CL and DY contributed to design
and coordinate the study, interpret the findings and draft the manuscript. LL
and HL contributed to draft the protocol and the statistical analysis. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by the National Nature Science Foundation of
China (No.81070645 and No. 30971393), University Scholar of the Medical
University of Tianjin (No. 2006ky43) and Tianjin Medical University of
Metabolic Disease Hospital Foundation. We appreciate technology assistance
of Professor Yuqin Yan, Mingfang Zhang and Yongming Wang. We also
greatly appreciate Professor Gareth Denyer in Sydney University who did a
comprehensive and in-depth professional English language editing.
Author details
1Key Laboratory of Hormone and Development (Ministry of Health),
Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin
Medical University, 66# TongAn Road, Heping District, 300070 Tianjin, China.
2Translational Research Center, Institute for Translational Medicine and
Therapeutics, Perelman School of Medicine at University of Pennsylvania,
Philadelphia, PA, USA.
Received: 2 June 2012 Accepted: 8 June 2012
Published: 19 June 2012
References
1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes:
estimates for the year 2000 and projections for 2030. Diabetes Care 2004,
27:1047–1053.
2. Bell DS: Heart failure: the frequent, forgotten, and often fatal
complication of diabetes. Diabetes Care 2003, 26:2433–2441.3. Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation 2007,
115(25):3213–3223.
4. Falcão-Pires I, Leite-Moreira AF: Diabetic cardiomyopathy: understanding
the molecular and cellular basis to progress in diagnosis and treatment.
Heart Fail Rev 2012, 17(3):325–344.
5. Rubler S, Dlugash J, Yuceoglu YZ: New type of cardiomyopathy associated
with glomerulosclerosis. Am J Cardiol 1972, 30:595–602.
6. Somaratne JB, Whalley GA, Poppe KK, ter Bals MM, Wadams G, Pearl A,
Bagg W: Doughty RN:Screening for left ventricular hypertrophy in
patients with type 2 diabetes mellitus in the community. Cardiovasc
Diabetol 2011, 14:10.
7. Boudina S, Abel ED: Diabetic cardiomyopathy, causes and effects. Rev
Endocr Metab Disord 2010, 11:31.
8. Dobrin JS, Lebeche D: Diabetic cardiomyopathy: signaling defects and
therapeutic approaches. Expert Rev Cardiovasc Ther 2010, 8:373–391.
9. Johansen JS, Harris AK, Rychly DJ, Ergul A: Oxidative stress and the use of
antioxidants in diabetes: linking basic science to clinical practice.
Cardiovasc Diabetol 2005, 4:5.
10. Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, Huang X, Xiao J, Li Y, Li Z:
Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats.
Cardiovasc Diabetol 2011, 10:69.
11. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME: Diabetic
cardiomyopathy: insights into pathogenesis, diagnostic challenges, and
therapeutic options. Am J Med 2008, 121:748–757.
12. Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: evidence,
mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543–567.
13. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ: Attenuation by
metallothionein of early cardiac cell death via suppression of
mitochondrial oxidative stress results in a prevention of diabetic
cardiomyopathy. J Am Coll Cardiol 2006, 48:1688–1697.
14. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA: Role of oxidative
stress in development of cardiovascular complications in diabetes
mellitus. Curr Vasc Pharmacol 2006, 4:215–227.
15. Kain V, Kumar S, Sitasawad SL: Azelnidipine prevents cardiac dysfunction
in streptozotocin-diabetic rats by reducing intracellular calcium
accumulation, oxidative stress and apoptosis. Cardiovasc Diabetol
2011, 10:97.
16. Obrosova I, Fathallah L, Greene D: Early changes in lipid peroxidation and
antioxidative defense in rat retina. Eur J Pharm 2000, 398:139–146.
17. Ghibu S, Richard C, Vergely C, Zeller M, Cottin Y, Rochette L: Antioxidant
Properties of an Endogenous Thiol: Alpha-lipoic Acid, Useful in the
Prevention of Cardiovascular Diseases. J Cardiovasc Pharmacol 2009,
54:391–398.
18. Li CJ, Zhang QM, Li MZ, Zhang JY, Yu P, Yu DM: Attenuation of myocardial
apoptosis by alpha-lipoic acid through suppression of mitochondrial
oxidative stress to reduce diabetic cardiomyopathy. Chin Med J (Engl)
2009, 122:2580–2586.
19. Bojunga J, Nowak D, Mitrou PS, Hoelzer D, Zeuzem S, Chow KU:
Antioxidative treatment prevents activation of death-receptor- and
mitochondrion-dependent apoptosis in the hearts of diabetic rats.
Diabetologia 2004, 47(12):2072–2080.
20. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD,
Besch HR Jr: Diabetes increases formation of advanced glycation end
products on Sarco(endo) plasmic reticulum Ca2+ -ATPase. Diabetes
2004, 53:463–473.
21. Schaible TF, Malhotra A, Bauman WA, Scheuer J: Left ventricular function
after chronic insulin treatment in diabetic and normal rats. J Mol Cell
Cardiol 1983, 15:445–458.
22. Kain V, Kumar S, Puranik AS, Sitasawad SL: Azelnidipine protects
myocardium in hyperglycemia-induced cardiac damage. Cardiovasc
Diabetol 2010, 9:82.
23. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN:
Overexpression of metallothionein reduces diabetic cardiomyopathy.
Diabetes 2002, 51:174–181.
24. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta Y, Yokota T,
Sunagawa K, Tsutsui H: Overexpression of glutathione peroxidase
attenuates myocardial remodeling and preserves diastolic function in
diabetic heart. Am J Physiol Heart Circ Physiol 2006, 291:H2237–H2245.
25. Shen X, Zheng S, Metreveli NS, Epstein PN: Protection of cardiac
mitochondria by overexpression of MnSOD reduces diabetic
cardiomyopathy. Diabetes 2006, 55:798–805.
Li et al. Cardiovascular Diabetology 2012, 11:73 Page 10 of 10
http://www.cardiab.com/content/11/1/7326. Ghibu S, Richard C, PharmD VC, Zeller M, Cottin Y, PharmD LR: Antioxidant
Properties of an Endogenous Thiol: Alpha-lipoic Acid, Useful in the
Prevention of Cardiovascular Diseases. J Cardiovasc Pharmacol 2009,
54:391–398.
27. Asbun J, Villarreal FJ: The pathogenesis of myocardial fibrosis in the
setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 47:693–700.
28. Zou P, Wu LL, Wu D, Fan D, Cui XB, Zhou Y, Wang C, Li L: High glucose
increases periostin expression and the related signal pathway in adult
rat cardiac fibroblasts. Acta Physiologica Sinica 2010, 62:247–254.
29. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y: Oxidative stress mediates
cardiac fibrosis by enhancing transforming growth factor-beta1 in
hypertensive rats. Mol Cell Biochem 2008, 317:43–50.
30. Petrov VV, Fagard RH, Lijnen PJ: Stimulation of collagen production by
transforming growth factor-beta1 during differentiation of cardiac
fibroblasts to myofibroblasts. Hypertension 2002, 39:258–263.
31. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH,
McClure CD, Spinale FG, Zile MR: Matrix metalloproteinases/tissue
inhibitors of metalloproteinases: relationship between changes in
proteolytic determinants of matrix composition and structural,
functional, and clinical manifestations of hypertensive heart disease.
Circulation 2006, 113:2089–2096.
32. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W,
Schwimmbeck PL, Kuhl U, Schultheiss HP: Dilated cardiomyopathy is
associated with significant changes in collagen type I/III ratio.
Circulation 1999, 99:2750–2756.
33. Berman M, Teerlink J, Li L, Mahimkar R, Zhu BQ, Nguyen A, Dahi S, Karliner J,
Lovett DH: Cardiac matrix metalloproteinase-2 expression independently
induces marked ventricular remodeling and systolic dysfunction. Am J
Physiol Heart Circ Physiol 2006, 292:H1847–H1860.
34. Bollano E, Omerovic E, Svensson H, Waagstein F, Fu M: Cardiac remodeling
rather than disturbed myocardial energy metabolism is associated with
cardiac dysfunction in diabetic rats. Int J Cardiol 2007, 114(2):195-201.
35. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T,
Schultheiss HP, Pauschinger M, Tschope C: Contributions of inflammation
and cardiac matrix metalloproteinase activity to cardiac failure in
diabetic cardiomyopathy: the role of angiotensin type 1 receptor
antagonism. Diabetes 2007, 56:641–646.
36. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U,
Fischer JW, Böhm M, Pauschinger M, Schultheiss HP, Tschöpe C: Reduced
MMP-2 activity contributes to cardiac fibrosis in experimental diabetic
cardiomyopathy. Basic Res Cardiol 2008, 103(4):319–327.
37. Tibbles LA, Woodgett JR: The stress-activated protein kinase pathways.
Cell Mol Life Sci 1999, 55:1230–1254.
38. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY: High glucose induced
apoptosis in human endothelial cells is mediated by sequential
activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation
2000, 101:2618–2624.
39. Dunlop ME, Muggli EE: Small heat shock protein alteration provides a
mechanism to reduce mesangial cell contractility in diabetes and
oxidative stress. Kidney Intl 2000, 57:464–475.
40. Thandavarayan RA, Watanabe K, Ma M, Gurusamy N, Veeraveedu PT, Konishi
T, Zhang S, Muslin AJ, Kodama M, Aizawa Y: Dominant-negative p38
{alpha} mitogen-activated protein kinase prevents cardiac apoptosis and
remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol
Heart Circ Physiol 2009, 297:H911–H119.
41. Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Mito S, Harima M,
Thandavarayan RA, Suzuki K, Nagata M, Takagi R, Watanabe K: Curcumin
prevents diabetic cardiomyopathy in streptozotocin-induced diabetic
rats: Possible involvement of PKC-MAPK signaling pathway. Eur J Pharm
Sci 2012, [Epub ahead of print].
doi:10.1186/1475-2840-11-73
Cite this article as: Li et al.: Cardiac fibrosis and dysfunction in
experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic
acid. Cardiovascular Diabetology 2012 11:73.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
